{
  "trial_id": "NCT00633698",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Male or female subjects, aged 18 - 75 years",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Subjects with and without cardiovascular diseases",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Lp(a) plasma levels > 30 mg/dl",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Triglyceride levels < 400 mg/dl",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Cholesterol and triglyceride levels not requiring immediate change in medication, according to current clinical guidelines",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "If concurrent statin therapy, stable doses are required in the four weeks prior study",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Subjects willing to follow all study procedures including attendance at practices for scheduled study visits, fasting prior to blood draws and compliance with study treatment regimen",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Written informed consent to participate in the trial",
      "label": "met",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Known hypertriglyceridaemia or fasting triglycerides >= 400 mg/dl in the last four weeks before the randomisation visit.",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Known heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia)",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Documented secondary hypercholesterolaemia of any cause",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Initiation of a lipid-modifying drug treatment or a dose change of a lipid-modifying drug within the last four weeks",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Known hypersensitivity to nicotinic acid or any component of this medication or their derivatives",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Concurrent treatment with products containing significant amounts (more than 100 mg as daily dose) of nicotinic acid (niacin) or nicotinamide (e.g., vitamin preparations and nutritional supplements)",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Concurrent treatment with an immediate release formulation of nicotinic acid or a nicotinic acid analogue, e.g. supplements",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Treatment with an anticoagulant such as marcumar",
      "label": "not_met",
      "evidence": ""
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "65",
    "trial_id": "NCT00633698",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}